Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7177869 | 0.89 | MAPT (0.38) | MAPTKMT2AMEN1TP53GLA | |
| SCHEMBL7200327 | 0.87 | MAPT (0.40) | MAPTKMT2AMEN1TP53GLA | |
| SCHEMBL8339941 | 0.71 | — | — | |
| SCHEMBL13248348 | 0.67 | MAPT (0.49) | MAPTKMT2AMEN1TP53GLA | |
| SCHEMBL7181038 | 0.67 | MAPT (0.49) | MAPTKMT2AMEN1TP53GLA | |
| SCHEMBL6947543 | 0.64 | MAPT (0.45) | MAPTKMT2AMEN1TP53GLA | |
| SCHEMBL2927941 | 0.64 | WDR5 (0.46) | MAPTKMT2ATP53NPC1RAB9A | |
| Lithium Ion SCHEMBL7175365 | 0.63 | MAPT (0.45) | MAPTKMT2AMEN1TP53GLA | |
| SCHEMBL19185513 | 0.63 | MAPT (0.46) | MAPTKMT2AMEN1TP53GLA | |
| SCHEMBL870366 | 0.63 | ALDH1A1 (0.44) | MAPTKMT2ATP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6600035-B1 | Multistage reaction of forming penicillin antibiotics | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-29 | — | — | US | claimed |
| US-6037469-A | BETA LACTAMASE INHIBITOR AND ANTIBACTERIAL; FOR TREATING BACTERIAL INFECTIONS IN HUMANS AND ANIMALS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-14 | — | — | US | claimed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| US-RE44874-E1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2014-04-29 | — | — | US | disclosed |
| EP-2042168-B1 | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8198483-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-7982067-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-7776895-B2 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| US-6037469-A | BETA LACTAMASE INHIBITOR AND ANTIBACTERIAL; FOR TREATING BACTERIAL INFECTIONS IN HUMANS AND ANIMALS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-14 | — | — | US | disclosed |
| US-5939066-A | TREATING OR PREVENTING A BACTERIAL INFECTION BY ADMINISTERING A LACTAMASE INHIBITORY EFFECTIVE AMOUNT OF A PENEM AND A LACTAM ANTIBIOTIC | SMITHKLINE BEECHAM P.L.C. | 1999-08-17 | — | — | US | disclosed |
| US-5911985-A | IN COMBINATION WITH CARRIERS AND A LACTAM ANTIBIOTIC | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-06-15 | — | — | US | disclosed |
| US-5776455-A | PENICILLIN BACTERICIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-07-07 | — | — | US | disclosed |
| EP-0758240-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING A BETA-LACTAMASE INHIBITING PENEM IN COMBINATION WITH A BETA-LACTAM ANTIBIOTIC AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-19 | — | — | EP | disclosed |
| US-5602250-A | ANTIBIOTICS, BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-02-11 | — | — | US | disclosed |
| WO-1995028935-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING A BETA-LACTAMASE INHIBITING PENEM IN COMBINATION WITH A BETA-LACTAM ANTIBIOTIC AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 1995-11-02 | — | — | WO | disclosed |
| EP-0666862-A1 | 6-(SUBSTITUTED METHYLENE) PENEMS AND INTERMEDIATES | SMITHKLINE BEECHAM PLC (GB) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994010178-A1 | 6-(SUBSTITUTED METHYLENE) PENEMS AND INTERMEDIATES | SMITHKLINE BEECHAM P L C (GB) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | HAVCR2, HDLBP, HSP90B1 | MAPT 3871/4885KMT2A 4163/4885MEN1 3879/4885 |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PNMT, HRH2, CHKB | MAPT 2476/4885KMT2A 257/4885MEN1 3658/4885 |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | MAPT 1794/4885KMT2A 369/4885MEN1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.